Effect of dutasteride on castration-resistant prostate cancer.

about

Effect of dutasteride on castration-resistant prostate cancer.

Item

http://www.wikidata.org/entity/Q49368361

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Effect of dutasteride on castration-resistant prostate cancer.

@en

Effect of dutasteride on castration-resistant prostate cancer.

@nl

type

Item

label

Effect of dutasteride on castration-resistant prostate cancer.

@en

Effect of dutasteride on castration-resistant prostate cancer.

@nl

prefLabel

Effect of dutasteride on castration-resistant prostate cancer.

@en

Effect of dutasteride on castration-resistant prostate cancer.

@nl

P1476

Effect of dutasteride on castration-resistant prostate cancer.

@en

P2093

Takeshi Azuma

http://www.w3.org/2001/XMLSchema#string

Yasuhi Nagase

http://www.w3.org/2001/XMLSchema#string

Yujiro Sato

http://www.w3.org/2001/XMLSchema#string

Yukihide Matayoshi

http://www.w3.org/2001/XMLSchema#string

P2860

Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer

Abiraterone in metastatic prostate cancer without previous chemotherapy

Increased survival with enzalutamide in prostate cancer after chemotherapy

Effect of dutasteride on the risk of prostate cancer.

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer.

Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride.

CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.

The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.

P304

133-136

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/MCO.2017.1480

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29387405

http://www.w3.org/2001/XMLSchema#string

P932

5769310

http://www.w3.org/2001/XMLSchema#string